Streetbeat News

Products Services

HZNP

Horizon Therapeutics reports positive topline data from Phase 3 clinical trial (OPTIC-J) in Japan for TEPEZZA (teprotumumab-trbw) in treating active thyroid eye disease (TED). At week 24, 89% of patients treated with TEPEZZA showed clinically meaningful improvement compared to 11% receiving placebo.

Portfolio Pulse from Benzinga Newsdesk

June 22, 2023 | 12:05 pm

APM

Aptorum Group has submitted the Phase 1b/2a clinical trial protocol of SACT-1, an orally administered repurposed small molecule drug for the treatment of neuroblastoma, to the US FDA. The trial will study SACT-1 in combination with chemotherapy for first relapse or refractory high-risk neuroblastoma patients.

Portfolio Pulse from Happy Mohamed

June 22, 2023 | 12:04 pm

LIFE

The European Commission has granted Orphan Drug Designation to aTyr Pharma's Efzofitimod for the treatment of systemic sclerosis. This designation provides regulatory and financial incentives for the development of the drug.

Portfolio Pulse from Bill Haddad

June 22, 2023 | 12:04 pm

JSPR

Jasper Therapeutics has announced the dosing of the first patient in a Phase 1 trial of Briquilimab for lower-risk myelodysplastic syndrome. This marks a significant milestone for the company's clinical development program.

Portfolio Pulse from Bill Haddad

June 22, 2023 | 12:03 pm

CDTX

Cidara Therapeutics has received FDA Fast Track designation for its novel drug-Fc conjugate, CD388, targeting Influenza A and B. This designation will expedite the development and review process for the drug.

Portfolio Pulse from Bill Haddad

June 22, 2023 | 12:01 pm

AAPL

Apple has fixed two security faults in iPhones and iPads that compromised thousands of devices in Russia. The company credited Kaspersky Lab for discovering the glitches. The fixes protect iPhones running iOS 15.7 or earlier, while more recent versions are already impervious to the attacks.

Portfolio Pulse from Anusuya Lahiri

June 22, 2023 | 11:55 am

QCOM

Qualcomm Technologies announced the launch of two modem chipsets with satellite capability, the Qualcomm 212S Modem and the Qualcomm 9205S Modem. These chipsets enable IoT enterprises, developers, ODMs, and OEMs to manage business projects using real-time information and insights.

Portfolio Pulse from Charles Gross

June 22, 2023 | 11:50 am

INM

InMed Pharmaceuticals announced Phase 2 trial results for its INM-755 CBN cream, stating that the results for non-wound itch were not statistically significant due to the anti-itch effect of the control cream.

Portfolio Pulse from Bill Haddad

June 22, 2023 | 11:37 am

ROIV

Roivant reports positive long-duration data for RVT-3101 from TUSCANY-2 Phase 2b study in ulcerative colitis, showing improved clinical remission and endoscopic improvement. The treatment was well tolerated and had a favorable safety profile.

Portfolio Pulse from Bill Haddad

June 22, 2023 | 11:36 am

ALZN

Alzamend Neuro plans to conduct two Phase II clinical trials to investigate the safety and efficacy of AL001 for patients with mild to moderate Alzheimer's disease.

Portfolio Pulse from Benzinga Newsdesk

June 22, 2023 | 11:31 am